|Chronic kidney disease (CKD) affects approximately 10% of the adult population in developed countries. Renal fibrosis plays a pivotal role in the development and progression of CKD as well as in renal transplant failure. Fibrosis results in the loss of organ architecture and function. It is the most damaging process in CKD. the COX-2/prostaglandin (PG) system plays a dominant role in the progression of renal injury. COX enzymes catalyze the conversion of arachidonic acid into prostaglandins, including prostaglandin E2 (PGE2), which is an important mediator of numerous physiological processes in the kidney, including renal hemodynamics as well as water and salt balance. PGE2 exerts its biological activity by activating several G protein-coupled prostanoid receptors, known as EP1-EP4. Several studies have demonstrated an important role for the EP1-EP4 receptors in renal injury. Butaprost is a selective EP2 agonist.||Butaprost is a selective EP2 agonist with a Ki of 2.4 μM for murine EP2 receptor. It is less activity against murine EP1, EP3 and EP4 receptors. Moreover, Butaprost mitigates TGF‐β‐induced epithelial-mesenchymal transition (EMT). It also reduces TGF-β-induced fibronectin (FN) expression, Smad2 phosphorylation and epithelial-mesenchymal transition in Madin-Darby Canine Kidney (MDCK) cells.A 83-01 Technical Information In addition, Butaprost attenuates the development of fibrosis in mice that underwent unilateral ureteral obstruction surgery, as illustrated by a reduction in the gene and protein expression of α-smooth muscle actin, fibronectin and collagen 1A1.Semaglutide MedChemExpress |In conclusion, stimulation of the EP2 receptor can effectively mitigate renal fibrogenesis in various fibrosis models.PMID:34596059 Butaprost successfully mitigates fibrogenesis in MDCK cells, UUO mice, and human PCKS. It also attenuates fibrosis by hampering TGF-β/Smad2 signaling.|Reference:|Michael Schou Jensen, et al. Acta Physiol (Oxf). 2019 Sep;227(1):e13291.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
|5-HT receptors are a group of G protein-coupled receptors and ligand-gated ion channels in the central nervous system and peripheral nervous system. They mediate excitatory and inhibitory neurotransmission. Specifically, Serotonin receptors exist in almost all animals, and can even regulate the longevity and behavioral senescence of Caenorhabditis elegans. Besides, 5-HT plays a variety of roles by binding to cell surface receptors. Cell surface receptors are including seven different families (5-HT1 to 5-HT7). Moreover, the 5-HT receptor plays an important role in various neuropsychiatric diseases, such as anxiety, depression, schizophrenia, migraine, and drug addiction. Furthermore, the 5-HT receptor may also play an important role in obesity, aggressive behavior, sexual behavior, and cardiovascular disease.|In the digestive tract, stimulation of the 5-HT4 receptor leads to a variety of effects, including promoting peristaltic reflex, guinea pig ileum, and so on. Meanwhile, the 5-HT4 receptor has a wide distribution of tissue and is positively coupled with adenylate cyclase. In the brain, the 5-HT4 receptor is located on neurons, many of which mediate the slow excitatory response to 5-HT. Nonetheless, 5-HT plays a physiological role in the regulation of gastrointestinal motility. Here, we will introduce a selective and competitive 5-HT4 antagonist, SB-203186.|SB-203186 is a Selective and Competitive 5-HT4 Antagonist.|Above all, SB-203186 antagonizes the 5-HT4 receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT. Importantly, it has pKB values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively.|Next in importance, SB-203186 with 10 μM pretreatment enhances the 5-HT-induced contractions of the antral stripes.Docetaxel Inducer Particularly, intraduodenally administered SB-203186 with 0.Bortezomib Formula 3-3 mg/kg to newborn Camborough piglets produced blockade of 5-HT-evoked tachycardia.PMID:35198811 Obviously, this was maximal after 20 min and lasted for more than 3 h with 0.3 mg/kg. Interestingly, SB-203186 with 0.1-3 mg/kg by i.v. surmountable antagonised 5-HT-evoked tachycardia in anesthetized Yucatan minipigs or newborn Camborough piglets with similar potency.|Once more, SB-203186 enhanced 5-HT-induced contractions in the antrum. In addition, sb203186 increased gastric fundus contraction induced by 5-HT, suggesting that the 5-HT4 receptor is involved in relaxation.|All in all, SB-203186 hydrochloride is a selective and competitive 5-HT4 antagonist.|References:|S G Parker, et al. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):28-35.|Tohru Komada, et al. Biol Pharm Bull. 2007 Mar;30(3):508-13.|MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
|The transcriptional enhanced associate domain (TEAD) is a transcription factor. In mammals, TEAD has four different isoforms namely TEAD1 (TEF-1/NTEF), TEAD2 (TEF-4/ETF), TEAD3 (TEF-5/ETFR-1), and TEAD4 (TEF-3/ETFR-2/FR-19). And there is a high degree of homology and expression pattern between TEAD1-4. The TEAD families regulate cell growth, proliferation, and tissue homeostasis via their transcriptional target genes. In addition, the transcriptional output of TEAD plays an important role in tumor progression, metastasis, cancer metabolism, and immunity. Therefore, TEAD is an important target for the treatment of human diseases including cancer and cardiovascular diseases.|TEAD coordinates with various signal transduction pathways, including Hippo, Wnt, TGFβ, and EGFR pathways. But so far, TEAD is a key transcription factor of the Hippo pathway. Because in the Hippo pathway, TEAD is activated by forming a complex with YAP1 or transcriptional coactivator with PDZ-binding motif (TAZ). Accordingly, the YAP1/TAZ-TEAD complex is a novel therapeutic target for cancer treatment.Navitoclax Description Moreover, the YAP1/TAZ-TEAD complex is also an effective therapeutic target for malignant pleural mesothelioma (MPM).K-975 is a potent, selective and orally active TEAD inhibitor.||K-975 effectively inhibits the protein-protein interactions between YAP1/TAZ and TEAD.Acetylcysteine medchemexpress And K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD.PMID:35196505 More importantly, K-975 exhibits antitumor activity in human MPM cell lines. K-975 strongly inhibits the reporter activity in NCI-H661/CTGF-Luc cells, but does not inhibit the reporter activity in NCI-H661/NRF2-Luc cells. In NCI-H226 cells, K-975 decreases the expressions of CTGF, IGFBP3, and NPPB mRNAs, and increases the expression of FBXO32 mRNA. Furthermore, K-975 potently inhibits the proliferation of NF2-non-expressing MPM cell lines. K-975 also strongly inhibits the proliferation of MSTO-211H cells, an NF2-expressing cell line.|To sum up, K-975 is a potent and orally active pan-TEAD inhibitor. K-975 shows anti-tumor effects by inhibiting YAP1/TAZ-TEAD signaling in SCID mice.|References：|[1] Ayumi Kaneda, et al. Am J Cancer Res. 2020 Dec 1;10(12):4399-4415.|[2] Hyunbin D Huh, et al. Cells. 2019 Jun 17;8(6):600.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
|More and more evidence suggesting that the adenosine A2A receptor is a promising target for antiparkinson treatment. Adenosine A2A receptors always locate within the caudate-putamen, nucleus accumbens, and olfactory tubercle. The concentration within the basal ganglia means a specific functional role for these receptors in neuronal communication. Especially, it plays an important role in motor behavior.|What’s more, the ability of adenosine A2A receptor antagonists to modulate basal ganglia neurotransmission has been proven in Parkinson’s disease (PD) model.Semaglutide Biological Activity For example, ST1535, is a potent adenosine A2A antagonist. It improves animal performance in a number of experimental models of PD. Furthermore, ST1535 potentiates contralateral turning behavior induced by L-DOPA in 6-OHDA-lesioned rats. It also reduces haloperidol-elicited catalezpsy.There exists a functional antagonism between A2A adenosine receptors and D2 dopamine receptors.Acute activation of D2 dopamine receptors can suppress cyclic AMP accumulation.Vincristine Epigenetics However, activation of A2A adenosine receptors stimulates its accumulation.PMID:35008123 Evaluation of the in vivo metabolic fate of ST1535 in rat and monkey plasma, including ST3932 (M2) and ST4206 (M3).ST4206 is a potent and orally active adenosine A2A antagonist.||ST4206 inhibits agonist-induced cAMP accumulation with an IC50 of 990 nM. And the IC50 values on cyclic AMP were 427 nM and 450 nM, respectively. Additionally, the Kis are 12 nM and 197 nM for adenosine A2A receptor and adenosine A1 receptor, respectively.ST4206 is orally active at concentrations of 10, 20, and 40 mg/kg in haloperidol-induced catalepsy in mice. And ST4206 antagonizes haloperidol-induced catalepsy, and increases motor activity in a dose-dependent manner. At dosages of 20 and 40 mg/kg, ST4206 significantly increases the number of contralateral turns induced by l-DOPA in rats.The metabolite of ST1535, ST4206, shows a pharmacological activity similar to ST1535 both in vitro and in vivo. It may act as a potential pharmacological alternative to ST1535|In conclusion, from a behavioral point of view, ST4206 is similarly effective as ST1535. The metabolite exhibits the same characteristics as the parent drug ST1535. Therefore, ST4206 has the potential for PD research.|Reference:|[1]. Stasi MA, et al. Eur J Pharmacol. 2015 Aug 15;761:353-61.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com
|Muscarinic M3 receptors are a subtype of Muscarinic acetylcholine receptors (mAChRs). Specifically, mAChRs is acetylcholine receptor, which forms a G-protein-coupled receptor complex in the cell membrane of some neurons and other cells. They play a variety of roles, including acting as the main terminal receptors for acetylcholine stimulation released by postganglionic fibers in the parasympathetic nervous system. Besides, M3 receptors are coupled with GQ-like G proteins and up-regulate phospholipase C.Docetaxel Protocol So it regulates inositol triphosphate and intracellular calcium as signaling pathways.|Moreover, direct stimulation of vascular smooth muscle M3 mediates vasoconstriction in the pathological process of vascular endothelium destruction. Furthermore, the Muscarinic M3 receptor regulates pancreatic insulin secretion, which is an important target to understand the mechanism of type 2 diabetes. Meanwhile, the M3 receptor is expressed in airway smooth muscle, submucous gland, and vascular endothelium. In M3R–/– knockout mice, the contraction of airway smooth muscle cells in response to ACh is mainly mediated by the M3 receptor. Here, we will introduce a selective and competitive muscarinic M3 receptor antagonist, CHF5407.|CHF5407 is a Muscarinic M3-Receptor Antagonist.|How does CHF5407 work on the target? Let’s study it together.Vincristine Inducer In the beginning, CHF5407 is a selective, long-acting and competitive muscarinic M3 receptor antagonist.PMID:35028340 Nonetheless, CHF5407 shows subnanomolar affinities for human muscarinic M1 (hM1), M2 (hM2), and M3 (hM3) receptors. Interestingly, CHF5407 shows a prolonged antibronchospastic activity.|In the second place, CHF5407 has a very slow dissociation from M3 receptors (hM3; t1/2=166 min). Importantly, CHF5407 has markedly short-acting at M2 receptors (hM2; t1/2=31 min). Particularly, CHF5407 produces a long-lasting inhibition of M3 receptor-mediated contractile responses to carbachol in the guinea pig isolated trachea and human isolated bronchus.|Last but not the least, CHF5407 with 0.1-1 nmol/kg by intratracheally exerted a dose-dependent and potent inhibition of ACh-induced (20 g/kg; i.v.) bronchospasm. Obviously, CHF5407 has an ED50 value of 0.15 nmol/kg in guinea pigs (450-550 g).|All in all, CHF5407 is a selective, long-acting and competitive muscarinic M3 receptor antagonist.|References:|G Villetti, et al. J Pharmacol Exp Ther. 2010 Dec;335(3):622-35.|MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com